Given that ER and progesterone receptor (PR) signaling are major promoters of cyclin D–CDK4/6 activity in HR+ BC cells [192], it was not unexpected that loss of ER/PR expression was associated with primary resistance to CDK4/6i in BC cell lines and tumor biopsy specimens [128,129]. The gene discussed is CDK4; the disease is breast cancer.